Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis
PurposeTo guide the drug selection for treatment of moderate to severe ulcerative colitis (UC) by evaluating the efficacy and safety of various drugs.MethodsThis systematic review searched the Embase, PubMed, The Cochrane Library, and Web of Science databases and included randomized controlled trial...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1481678/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561009807949824 |
|---|---|
| author | Wenkai Zhang Wenkai Zhang Songbo Zhao Songbo Zhao Jipin Li Jipin Li Yihua Sun Yihua Sun Xiang Wang Xiang Wang |
| author_facet | Wenkai Zhang Wenkai Zhang Songbo Zhao Songbo Zhao Jipin Li Jipin Li Yihua Sun Yihua Sun Xiang Wang Xiang Wang |
| author_sort | Wenkai Zhang |
| collection | DOAJ |
| description | PurposeTo guide the drug selection for treatment of moderate to severe ulcerative colitis (UC) by evaluating the efficacy and safety of various drugs.MethodsThis systematic review searched the Embase, PubMed, The Cochrane Library, and Web of Science databases and included randomized controlled trials (RCTs) based on the drugs used alone or in combination for treating UC. Moreover, the Stata17.0 software was employed for statistical analysis and results were reported as relative risk (RR) and 95% confidence interval (CI).ResultsFor the efficacy of induction, upadacitinib ranked first in clinical response, clinical remission, and endoscopic improvement rates, with cumulative probabilities of 96.0%, 99.3%, and 99.0%, respectively. Moreover, for the efficacy of maintenance, upadacitinib ranked first in both clinical remission and endoscopic improvement with a cumulative probability of 93.2% and 93.3%, respectively. For safety, vedolizumab showed the best incidence of adverse events (AE) with 16.8% cumulative probability, while upadacitinib showed the best incidence of serious adverse events (SAE) with 13.8% cumulative probability.ConclusionIn a systematic review and network meta-analysis, we found upadacitinib showed the best efficacy and safety in to be ranked highest in patients with moderate to severe ulcerative colitis. More trials of direct comparisons are needed to inform clinical decision making with greater confidence. |
| format | Article |
| id | doaj-art-0031cae38e814a50af67964aeba52574 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-0031cae38e814a50af67964aeba525742025-01-03T06:47:14ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.14816781481678Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitisWenkai Zhang0Wenkai Zhang1Songbo Zhao2Songbo Zhao3Jipin Li4Jipin Li5Yihua Sun6Yihua Sun7Xiang Wang8Xiang Wang9The Second Clinical College of Lanzhou University, Lanzhou, Gansu, ChinaDepartment of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, Gansu, ChinaThe Second Clinical College of Lanzhou University, Lanzhou, Gansu, ChinaDepartment of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu, ChinaThe Second Clinical College of Lanzhou University, Lanzhou, Gansu, ChinaDepartment of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu, ChinaThe Second Clinical College of Lanzhou University, Lanzhou, Gansu, ChinaDepartment of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, Gansu, ChinaThe Second Clinical College of Lanzhou University, Lanzhou, Gansu, ChinaDepartment of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, Gansu, ChinaPurposeTo guide the drug selection for treatment of moderate to severe ulcerative colitis (UC) by evaluating the efficacy and safety of various drugs.MethodsThis systematic review searched the Embase, PubMed, The Cochrane Library, and Web of Science databases and included randomized controlled trials (RCTs) based on the drugs used alone or in combination for treating UC. Moreover, the Stata17.0 software was employed for statistical analysis and results were reported as relative risk (RR) and 95% confidence interval (CI).ResultsFor the efficacy of induction, upadacitinib ranked first in clinical response, clinical remission, and endoscopic improvement rates, with cumulative probabilities of 96.0%, 99.3%, and 99.0%, respectively. Moreover, for the efficacy of maintenance, upadacitinib ranked first in both clinical remission and endoscopic improvement with a cumulative probability of 93.2% and 93.3%, respectively. For safety, vedolizumab showed the best incidence of adverse events (AE) with 16.8% cumulative probability, while upadacitinib showed the best incidence of serious adverse events (SAE) with 13.8% cumulative probability.ConclusionIn a systematic review and network meta-analysis, we found upadacitinib showed the best efficacy and safety in to be ranked highest in patients with moderate to severe ulcerative colitis. More trials of direct comparisons are needed to inform clinical decision making with greater confidence.https://www.frontiersin.org/articles/10.3389/fphar.2024.1481678/fullulcerative colitisdrug treatmentefficacysafetynetwork meta-analysis |
| spellingShingle | Wenkai Zhang Wenkai Zhang Songbo Zhao Songbo Zhao Jipin Li Jipin Li Yihua Sun Yihua Sun Xiang Wang Xiang Wang Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis Frontiers in Pharmacology ulcerative colitis drug treatment efficacy safety network meta-analysis |
| title | Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis |
| title_full | Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis |
| title_fullStr | Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis |
| title_full_unstemmed | Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis |
| title_short | Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis |
| title_sort | network meta analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis |
| topic | ulcerative colitis drug treatment efficacy safety network meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1481678/full |
| work_keys_str_mv | AT wenkaizhang networkmetaanalysisofefficacyandsafetyofdrugsforthetreatmentofmoderatetosevereulcerativecolitis AT wenkaizhang networkmetaanalysisofefficacyandsafetyofdrugsforthetreatmentofmoderatetosevereulcerativecolitis AT songbozhao networkmetaanalysisofefficacyandsafetyofdrugsforthetreatmentofmoderatetosevereulcerativecolitis AT songbozhao networkmetaanalysisofefficacyandsafetyofdrugsforthetreatmentofmoderatetosevereulcerativecolitis AT jipinli networkmetaanalysisofefficacyandsafetyofdrugsforthetreatmentofmoderatetosevereulcerativecolitis AT jipinli networkmetaanalysisofefficacyandsafetyofdrugsforthetreatmentofmoderatetosevereulcerativecolitis AT yihuasun networkmetaanalysisofefficacyandsafetyofdrugsforthetreatmentofmoderatetosevereulcerativecolitis AT yihuasun networkmetaanalysisofefficacyandsafetyofdrugsforthetreatmentofmoderatetosevereulcerativecolitis AT xiangwang networkmetaanalysisofefficacyandsafetyofdrugsforthetreatmentofmoderatetosevereulcerativecolitis AT xiangwang networkmetaanalysisofefficacyandsafetyofdrugsforthetreatmentofmoderatetosevereulcerativecolitis |